Nosocomial Pneumonia Clinical Trial
Official title:
Optimizing Dosing Regimen of Piperacillin/Tazobactam, Prolonged Infusion vs. Regular Infusion, Every 6 Hours, for Nosocomial Pneumonia in ICU Caused by Susceptible Pathogens With Higher MIC
1. To observe clinical and bacteriologic responses of different regimens of
piperacillin/tazobactam (4.5g q6h, prolonged or intermittent infusion) for treatment of
nosocomial pneumonia.
2. To describe the pharmacokinetic profile of piperacillin/tazobactam (4.5g q6h, prolonged
or intermittent infusion) in patients with nosocomial pneumonia.
3. To assess the safety profiles of piperacillin/tazobactam 4.5g q6h, prolonged or
intermittent infusion in patients with nosocomial pneumonia.
Enrolled patients will be randomized into therapeutic or controlled group. Controlled group
will receive piperacillin/tazobactam of 4.5g Q6h, intermittent infusion for 30 minutes.
Therapy group will receive piperacillin/tazobactam of 4.5g Q6h, prolonged infusion for 4
hours. The duration is 7-14 days.
Two sets of blood cultures (for aerobic and anaerobic culture) were obtained before the
study and post-treatment period if first blood culture is positive. Cultures from the lower
respiratory tract infection were obtained before (within 48 h) the study and on the last day
of therapy. The lower respiratory tract specimens obtained either by endotracheal
aspiration, bronchoalveolar lavage (BAL), a protected brush procedure (PBP) or as sputum
were required to show > 25 polymorphonuclear cells and < 10 squamous epithelial cells per
field (at 100× magnification).
The plasma concentration of piperacillin and tazobactam will be determined by LC/MS/MS
method. The QC samples will also be analyzed simultaneously with each run for the method
stability testing, according to the laboratory standard procedure.
;
Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04488510 -
Pathogens Involved in Secondary Infections During Severe Forms of Covid-19 Pneumonia:
|
||
| Completed |
NCT02598609 -
SEPREVEN: a Stepped-wedge Randomised Controlled Trial
|
N/A | |
| Completed |
NCT01431326 -
Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care
|
||
| Completed |
NCT06162455 -
High-dose Inhaled NO Therapy for the Prevention of Nosocomial Pneumonia After Cardiac Surgery With CPB
|
N/A | |
| Terminated |
NCT01897792 -
Effect of Antioxidant Vitamins on Coagulopathy and Nosocomial Pneumonia After Severe Trauma
|
Phase 2 | |
| Completed |
NCT01363271 -
Cost Study of Linezolid Versus Vancomycin Among Previously Hospitalized Patients
|
Phase 4 | |
| Recruiting |
NCT00842478 -
Effectiveness of Dental Brushing for Preventing Ventilator-Associated Pneumonia
|
Phase 2/Phase 3 | |
| Completed |
NCT00610324 -
Effect of Oral Decontamination Using Chlorhexidine or Potassium Permanganate in ICU Patients
|
Phase 4 | |
| Completed |
NCT04279873 -
Use of Microscopy, Cultures and Molecular Biological Methods for Diagnosing Nosocomial Pneumonia
|
||
| Completed |
NCT03303937 -
Characteristics of Lower Respiratory Tract Escherichia Coli Isolates in Mechanically Ventilated Intensive Care Patients
|
N/A | |
| Recruiting |
NCT06170372 -
High-dose Inhalations of Nitric Oxide in the Treatment of Pneumonia
|
N/A | |
| Completed |
NCT00829842 -
Oral Hygiene With Chlorhexidine and Incidence of Ventilator-Associated Pneumonia in Children Submitted to Heart Surgery
|
Phase 3 | |
| Recruiting |
NCT06261827 -
High-dose Inhaled NO Therapy for the pREvenvention of NP After Cardiac Surgery Under CPB
|
N/A | |
| Completed |
NCT05928208 -
The Role of Point-of-care Polymerase Chain Reaction in Managing Nosocomial Pneumonia
|
||
| Completed |
NCT02793141 -
International Study on NoSocomial Pneumonia in Intensive CaRE (PneumoINSPIRE)
|
||
| Completed |
NCT00236834 -
A Study of the Safety and Effectiveness of Levofloxacin Compared With Imipenem/Cilastatin in Patients With Pneumonia Acquired During Hospitalization
|
Phase 3 | |
| Not yet recruiting |
NCT06310941 -
Mechanical Insufflation-exsufflation and Hypertonic Saline in Nosocomial Bacterial Respiratory Tract Infection
|
N/A | |
| Completed |
NCT02413242 -
Advanced Understanding of Staphylococcus Aureus and Pseudomonas Aeruginosa Infections in EuRopE - ICU
|
||
| Recruiting |
NCT04223752 -
Safety and Pharmacokinetics of Ceftolozane/Tazobactam in Pediatric Participants With Nosocomial Pneumonia (MK-7625A-036)
|
Phase 1 |